BGLAP and depressive symptom measurement: Osteoblast-derived uncarboxylated osteocalcin (ucOCN) traverses the BBB to modulate neurotransmitter production and neurotrophic factor expression, thereby affecting depression pathogenesis and therapeutic outcomes as referenced in Figure 2[26,27].